The impact of community pharmacy dispensing fees on the introduction of buprenorphine – naloxone in Australia

References

• Barnett P G, Rodgers J H, Bloch D A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96: 683–690
   PubMed Web of Science ®Google Scholar
• Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stizer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290–1297
   PubMed Web of Science ®Google Scholar
• Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; 2, CD002207.pub2. DOI: 10.1002/14651858
   Google Scholar
• Newman R G, Whitehill W B. Double-blind comparisons of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2: 485–488
   PubMed Web of Science ®Google Scholar
• Ward J, Mattick R, Hall W. Key issues in methadone maintenance treatment. NSW University Press, NSW, Australia 1992
   Google Scholar
• Ward J, Mattick R P, Hall W. The effectiveness of methadone maintenance treatment: an overview. Drug Alcohol Rev 1994; 13: 327–336
   PubMedGoogle Scholar
• West S L, O'Neal K K, Graham C W. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000; 12: 405–414
   PubMedGoogle Scholar
• Booth R E, Corsi K F, Mikulich-Gilbertson S K. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend 2004; 74: 177–185
   PubMed Web of Science ®Google Scholar
• Chutuape M A, Silverman K, Stitzer M L. Effects of urine testing frequency on outcome in a methadone take-home contingency program. Drug Alcohol Depend 2001; 62: 69–76
   PubMed Web of Science ®Google Scholar
• Ezard N, Lintzeris N, Odgers P, et al. An evaluation of community methadone services in Victoria, Australia: results of a client survey. Drug Alcohol Rev 1999; 18: 417–423
   Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Elk R, Schmitz J, Creson D. Clinicwide and individualized behavioral interventions in drug dependence treatment. NIDA Res Monogr 1993; 137: 37–72
   Google Scholar
• Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mount Sinai J Med 2000; 67: 347–364
   PubMed Web of Science ®Google Scholar
• Maddux J F, Prihoda T J, Desmond D P. Treatment fees and retention on methadone maintenance. J Drug Issues 1994; 24: 429–443
   Web of Science ®Google Scholar
• Pani P P, Pirastu R, Ricci A, Gessa G L. Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. Drug Alcohol Depend 1996; 41: 81–84
   PubMed Web of Science ®Google Scholar
• Rhoades H M, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88: 34–39
   PubMed Web of Science ®Google Scholar
• Ritter A, Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev 2005; 24: 347–352
   PubMed Web of Science ®Google Scholar
• Robles E, Miller F B, Gilmore-Thomas K K, McMillan D E. Implementation of a clinic policy of patient-regulated methadone dosing. J Subst Abuse Treat 2001; 20: 225–231
   PubMed Web of Science ®Google Scholar
• NSW Department of Health. New South Wales Opioid Treatment Program clinical guidelines for methadone and buprenorphine treatment of opioid dependence. NSW Department of Health, Sydney 2006
   Google Scholar
• Winstock A R, Bell J. Clinical guidelines assessing suitability for unsupervised medication doses for treating opioid dependency. Royal Australasian College of Physicians and Australasian Chapter of Addiction Medicine, Sydney 2006
   Google Scholar
• Fountain J, Strang J, Gossop M, Farrel M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000; 95: 393–406
   PubMed Web of Science ®Google Scholar
• Mendelson J, Jones R T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?. Drug Alcohol Depend 2003; 70: S29–S37
   Web of Science ®Google Scholar
• Compton P, Ling W, Moody D, Chiang N. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 2006; 82: 25–31
   PubMed Web of Science ®Google Scholar
• Strain E C, Moody D E, Stoller K B, Walsh S L, Bigelow G E. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 2004; 74: 37–43
   PubMed Web of Science ®Google Scholar
• Fiellin D A, O'Connor P G. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002; 137: 688–692
   PubMed Web of Science ®Google Scholar